Showing posts with label Vaccine. Show all posts
Showing posts with label Vaccine. Show all posts

Friday, 26 February 2021

A Quite Possibly Wonderful Summer

Time to Rejoice 

 

Families will gather. Restaurants will reopen. People will travel. The pandemic may feel like it’s behind us—even if it’s not.

 

The summer of 2021 is shaping up to be historic.

After months of soaring deaths and infections, COVID-19 cases across the United States are declining even more sharply than experts anticipated. This is expected to continue, and rates of serious illness and death will plummet even faster than cases, as high-risk populations are vaccinated. Even academics who have spent the pandemic delivering ominous warnings have shifted their tone to cautiously optimistic now that vaccination rates are exploding.

Until very recently, Anthony Fauci had been citing August as the month by which the U.S. could vaccinate 70 to 80 percent of the population and reach herd immunity. Last week, he suddenly threw out May or early June as a window for when most Americans could have access to vaccines. Despite some concerns about new coronavirus variants, Ashish Jha, the dean of the Brown University School of Public Health, told me that he doesn’t see viral mutation as a reason to expect that most people couldn’t be well protected within that time frame.

If all of this holds true, it would mean that many aspects of pre-pandemic life will return even before summer is upon us. Because case numbers guide local policies, much of the country could soon have reason to lift many or even most restrictions on distancing, gathering, and masking. Pre-pandemic norms could return to schools, churches, and restaurants. Sports, theater, and cultural events could resume. People could travel and dance indoors and hug grandparents, their own or others’. In most of the U.S., the summer could feel … “normal.”

The feeling could even go beyond that. The pain wrought by the virus has differed enormously by location, race, and class, but a global pandemic still may be as close as the world can come to a shared tragedy. Periods of intense hardship are sometimes followed by unique moments of collective catharsis or awakening. The 1918 influenza that left the planet short of some 50 million people—several times as many as had just been killed in a gruesome war—gave way to the Roaring ’20s, when Americans danced and flouted Prohibition, hearing the notes that weren’t being played. For some, the summer of 2021 might conjure that of 1967, when barefoot people swayed languidly in the grass, united by an appreciation for the tenuousness of life. Pre-pandemic complaints about a crowded subway car or a mediocre sandwich could be replaced by the awe of simply riding a bus or sitting in a diner. People might go out of their way to talk with strangers, merely to gaze upon the long-forbidden, exposed mouth of a speaking human.

In short, the summer could feel revelatory. The dramatic change in the trajectory and tenor of the news could give a sense that the pandemic is over. The energy of the moment could be an opportunity—or Americans could be dancing in the eye of a hurricane.


The life expectancy in the United States is now a year shorter than before COVID-19. No other country has endured so much death and illness. But for all the failures that led to this point, the U.S. does finally seem to be experiencing some protective effects of population-level immunity. Recent research from Columbia University estimates that the U.S. is already much closer to Fauci’s stated threshold of 70 to 80 percent than our case numbers suggest. Owing to minimal and patchwork testing efforts, lead researcher Jeff Shaman told me, the actual number of infections in the U.S. has likely been about five times higher than reported. This would mean that about one in three Americans has already been infected by SARS-CoV-2. This does not alter the goal of vaccinating as many people as possible, but it does mean that while vaccines are rolling out, transmission rates should fall much more rapidly than if the population were all totally susceptible to the virus.

In some parts of the United States that have been hit extremely hard by the virus, the numbers give a sense that—if vaccination continues apace—the worst is behind us in those areas. In North and South Dakota, where leaders have been reluctant to require preventive measures, the per capita death rate is about 34 percent higher than the national average, and 13 percent of the population has had a confirmed case. “That probably means that 60 or 65 percent of the population has been infected there,” Shaman said. “That could mean they’re creeping up on herd immunity.” Indeed, North Dakotans have seen relatively few cases this winter, even while most of the U.S. saw a horrific surge. The state’s mask mandate expired a month ago. For the past six days, the state has reported zero COVID-19 deaths.

The warming weather and longer days should also decrease transmission. In much of the world, summers have proved safer than winters during the pandemic, “apparently by virtue of how much time people spend outdoors, and how likely they are to keep windows open and have fresh air circulating,” says Saad Omer, a vaccinologist and the director of the Yale Institute for Global Health. Light and heat can kill the virus directly, but their main effect seems to be making the world more hospitable for us simply to go outside, be social, move our bodies, and improve our baseline levels of health.

Although most experts are hesitant to make concrete predictions about exactly when the U.S. can consider its outbreak over, personal plans can be revealing. Jha has famously been hoping to have a July 4 barbecue in his backyard, including 20 people. By August, he told me, he hopes to travel with his family. The pandemic expert and former assistant secretary of homeland security Juliette Kayyem told me much the same last month: “I have plans to travel abroad in August. I feel like the world will start to move well before then.”

Where exactly that world is going, however, is far from certain. A beautiful, COVID-free summer may be a vision of hope, and possibly a reality for many, but optimistic projections about the coming months in the U.S. can mean losing sight of a far more unsettling global picture. As things get better, the world could fall into the same patterns that got us to the point of nearly half a million American deaths. “I’m feeling generally optimistic for the U.S. this summer,” Omer says. “But I’m also having nightmares.”


Under no circumstances is the coronavirus simply going to disappear this summer. Cases will drop, and restrictions will lift in many places. But rather than an abrupt end to the pandemic, the coming months will be more like the beginning of an extended and still-volatile tail of the outbreak globally. What that will look like, and how long it will last, depends on how nations cooperate and coordinate—or fail to. Regardless of how quickly the immediate threat of viral illness subsides in the U.S., America’s choices in the coming weeks and months could mean the difference between a pandemic that ends this year and one that haunts everyone indefinitely.

Though Shaman’s projections about herd immunity may sound hopeful, the fact that the U.S. was able to identify such a small fraction of our cases is evidence of profound, persistent failures in detection, communication, and prevention. Rapid testing will be key to containing local outbreaks, especially next fall and winter. This infrastructure is not yet in place, nor do many Americans have easy access to high-quality masks. We also have a far-from-impeccable record of accepting lifesaving vaccines when they are on offer. Even assuming that almost everyone gets their shots as soon as possible, the Columbia researchers estimate that in the U.S. alone, roughly 29 million additional cases could occur between now and July, depending on how Americans decide to act and which restrictions states choose to lift. “We should really be redoubling our efforts to control the virus,” Shaman said.

Variant strains that increase the transmissibility of the virus could also throw these estimates off, Shaman noted. As the virus mutates, the reliability of immunity from prior infections also changes. The recent outbreak in Manaus, Brazil, suggested that even high levels of past infection didn’t necessarily protect a population for long. Fundamentally, we still do not know how herd immunity will work—if it even does. “The most important thing to remind ourselves of is that herd immunity is only relevant to consider if we have a vaccine that blocks transmission,” says Shweta Bansal, a biologist at Georgetown University. If it turns out that vaccinated people can still carry and spread the virus, then a group cannot assume that they are protected because people around them are vaccinated. It would mean that the finish line is not 70 percent, but 100.

In the absence of a mythically perfect vaccine, the value of each dose depends almost entirely on how that dose is deployed. The situation in North Dakota, for example, stands in stark contrast to Vermont, where only 2 percent of the population has had a documented infection. In a place with low levels of immunity, each dose of the vaccine is more valuable than it would be elsewhere—more likely to save a life or prevent a chronic disease. The Trump administration’s approach to vaccination, since inherited by Joe Biden, was to leave it up to states to handle distribution individually, rather than allocate based on where the vaccines could have the biggest impact. Such an approach leaves pockets of the country open to surges in death and disease, despite national averages falling. As Bansal put it, even assuming that the vaccines do make herd immunity possible, the path will not be a straight line so much as “playing a game of whack-a-mole with COVID outbreaks.”

If the differences in vulnerability are significant between towns, counties, and states, the global disparities are chasms. Vietnam, for example, is a country of 97 million people that has had fewer than 1,600 cases of COVID-19 and 35 deaths. They have done an exemplary job of controlling the virus, and presumably have very low levels of immunity. Nonetheless, the current scheme of vaccine production—wherein every country is on its own to produce or procure vaccines from private companies selling them at a profit—leads to redundancies at every level, from innovation to distribution, and severe misallocation when comparing one population with another. The coming months could see, for instance, vaccines going to healthy 20-year-olds in North Dakota before much older, chronically ill people in places such as Vietnam. Americans might have to wonder whether we’ll need to wait until April or May to get shots, but many low-income countries may not have widespread access until 2022, or possibly even 2023, notes Ruth Faden, a bioethics professor at Johns Hopkins University.

This haphazard approach will mean deaths among high-risk people around the world who could’ve been saved by doses that went to teenage Americans this summer. “From a standpoint of global equity, this is profoundly wrong,” Faden says. Morality aside, it’s also dangerous for everyone. Providing the virus with new places to spread will allow it to linger with us indefinitely. The longer it sticks around, the more time it has to mutate—which is bad news for the entire world, Americans included. “As long as there are large swaths of people who are unprotected, then we’re going to see variants continue to pop up,” Faden says. “And it’s likely that some of those variants will evolve to escape the power of vaccines.”


If we are lucky, year over year, SARS-CoV-2 will evolve to cause milder disease than it has these past two years. That would be consistent with the virus that spread in 1918, which became the seasonal flu. It never again produced the same level of mortality as it did during its first two years, but the virus continues to evolve and kill hundreds of thousands of people every year. Most of us have come to accept this as inevitable.

For the coronavirus, that fate is not yet entirely sealed. It could still be avoided if we can draw as close as possible to global herd immunity, not a patchwork of immunized nations. This would require a unified effort of governments and pharmaceutical companies to ramp up vaccine production and coordinate distribution. “The reason we have to do all this careful rationing of the vaccines is that the supply is constrained, and the logistics of distribution weren’t worked out in advance,” says Ed Kaplan, a professor at Yale School of Management who has worked extensively in bioterrorism preparedness. “You need a centralized strategy.”

Many experts see the United States as singularly positioned to make this happen. “We need to get vaccine manufacturers together and increase production tenfold,” Jha, the dean at Brown, told me, “and the World Health Organization isn’t going to do it.” The WHO has aligned with other groups to form an advocacy network called COVAX, which has relied on donated doses from countries such as Russia and India, while the U.S. and Canada are focused on building up their own supplies. But no other country has the combination of wealth, influence, and infrastructure to orchestrate a definitive, global vaccination movement, Jha said. “Only the U.S. could lead an effort like that.”

After President Donald Trump abandoned the World Health Organization, abdicating responsibility to the global community and squandering American credibility, Biden promised to rebuild the country’s reputation as a leader in health and humanitarian efforts. So far, though, his vaccination approach has been emphatically “America first,” having negotiated deals to secure doses for everyone within our borders, with little mention of a pandemic beyond them. Public-health experts have proposed what a more ambitious initiative might look like, based on the way the U.S. invested in the HIV pandemic. Biden could establish the President’s Emergency Plan for Vaccine Access and Relief, or PEPVAR, modeled on the PEPFAR strategy to lead global AIDS eradication, which has been a boon for U.S. diplomacy as well as global health.

As opposed to simply donating money or a certain number of vaccines, the U.S. could build a coalition that can actually solve this problem—and stand ready to address any emerging variants or new coronaviruses in the coming months and years. “We will look back with regret on the months the U.S. wasted by not engaging globally,” says Omer, the Yale vaccinologist. “It’s a leadership opportunity. What better moment to rally the world?”

This is what could truly make the summer historic. Instead of aspiring to go back to the way things were, we go forward to how things could be. The canonical image of the Summer of Love may be most useful as a cautionary tale. In 1967, a visible minority listened to the Grateful Dead and discovered LSD, but their anti-war sentiment did not stop the U.S. from bombing civilians in Southeast Asia, and Richard Nixon won the White House the following year.* The post-pandemic 1920s gave way to yet another war, and a world that would later be unprepared for a global outbreak of a deadly respiratory virus, despite 100 years’ notice.

This summer could bring cause for celebration over not simply having made it through this morbid winter alive, but having built a system that can end this pandemic—and stop the next one. It could be when we ensure that no plague of this magnitude happens again.


* This article previously misstated the year Richard Nixon won the presidency.


Related Podcast

Listen to James Hamblin on an episode of Social Distance, the podcast from The Atlantic about the pandemic:

Subscribe to Social Distance to receive new episodes as soon as they’re published.

James Hamblin, M.D., is a staff writer at The Atlantic. He is also a lecturer at Yale School of Public Health, co-host of Social Distance, and author of Clean: The New Science of Skin.
Connect

Saturday, 2 January 2021

5 Things You Must Do While You Wait for the COVID-19 Vaccine

5 Things You Must Do While You Wait for the COVID-19 Vaccine:

 

 


 Photo by:  Hakan Nural

Newswise — Even as vaccinations against COVID-19 begin, the virus continues to kill thousands of Americans every day, making it more important than ever to stay safe and be ready in case it strikes you or your family.

“We can’t let our guard down while we wait our turn for the vaccine,” says rehabilitation psychologist Abigail Hardin, PhD. This is especially important given that the vaccines don’t take full effect (around 95% immunity) until days or weeks a number of days after the second dose. Continuing to take protective measures like social distancing and masking will help protect you, your loved ones and the community while you wait for your first dose and for the vaccine to take full effect.

Hardin counsels critically ill COVID patients at Rush University Medical Center when they move from intensive care to the rehabilitation unit and as they to recover at home. Seeing firsthand the toll the disease takes on families inspired her to write A Guide to COVID-19 to help people manage and overcome the illness through knowledge and preparation.

She recommends taking a few key steps now to reduce some of the challenges and anxieties that come with a serious illness.

1. Pretend you know you’re going to get sick.

Ideally, you won’t actually get sick, but you will have far less to worry about if your house is in order and you have a plan for what you’ll do if you or a family member tests positive for COVID-19. A good way to start is by answering these questions:

  • Where will you quarantine?
  • If you are a caregiver, who will take care of your children or elderly relatives?
  • Where is your insurance card?
  • What in-network hospital would you choose
  • Who needs to know you’re ill — and whom might you have exposed to the virus  

2. Pack a COVID-19 kit.

Having a COVID-19 kit for yourself and your family members will put your mind at ease. This can be especially helpful for an elderly parent or grown child who’s away at college, just as you might want them to have an emergency kit in their car or a supply of food and necessities on hand before a blizzard.

“Our brains don’t work as well when we’re under stress,” says Hardin. “It’s much easier to handle a tough situation when you have what you need ready.”

If you don’t end up using your kit, at least you’ll have copies of your insurance card, driver’s license and prescriptions; a pen and notebook; an extra set of comfy clothes; and a phone charger ready should you need them.

3. Assess and address your health.

You want to be at your strongest in case you become ill and be at your best to help care for family members if they need you.

  • While anyone can suffer a serious case of COVID-19, certain underlying conditions, such as obesity, high blood pressure and diabetes, are associated with severe illness or long-term effects. If you get your blood pressure or blood sugar levels under control now, you reduce your risks of complications later.
  • Adding a few simple habits to your daily routine, such as getting more sunshine and creating a sleep schedule to make sure you’re getting optimal rest, can improve your health and boost your immunity.
  • Finally, if you smoke, quit, and if you drink alcohol, do so in moderation (one drink a day for women and two for men.) 

4. Tackle the tough questions now.

“Thinking about death can be overwhelming,” Hardin says. “But preparing a will and talking through what care you would want if you were very ill now can save your loved one from the pain of trying to decide for you without knowing what you would want.”

Every adult needs a will and an advance directive. There are several types of advance directives: a living will, medical power of attorney/durable power of attorney for health care, do not resuscitate (DNR) order and practitioner order for life-sustaining treatment (POLST). Choose someone you trust to have “power of attorney” and make health care decisions on your behalf in case you cannot communicate for yourself.

Once you’ve tackled the tough decisions, the paperwork is simple. Your family lawyer can create these documents for you, but there are other ways that cost little or no money. The state of Illinois provides forms online, as do groups such as AARP. You can also download advance directive forms via the Rush Center for Excellence in Aging website or the Rush Copley Medical Center Advance Directives page.

The spiritual care teams at some hospitals, including the Rush hospitals, offer support for talking through these topics.

5. Stay strong mentally and emotionally.

The pandemic has disrupted our lives for close to a year, separating us from family and friends, canceling events and celebrations, closing businesses, putting millions out of work and costing 300,000+ lives in the U.S. alone. Add in the social stressors, from racism to political strife, and 2020 has been an extraordinarily challenging year.

"While you can’t self-care your way out of major life stressors, there are things you can do to reduce the impact of external events on your emotions," Hardin says.

Schedule times to regularly connect with family and friends remotely. Call a friend when you’re lonely, or find a therapist if you need to talk. Importantly, if you or a family member is struggling to cope, feeling helpless or hopeless, reach out for professional help. Your mental and emotional health will help you through whatever comes next.

“I’ve been with patients as they’ve fought and survived COVID-19,” Hardin says. “Knowing what to expect and being prepared can only help you to survive and thrive.”

 

 


Tuesday, 29 October 2019

Flu antibody protects against numerous and wide-ranging strains

Flu antibody protects against numerous and wide-ranging strains:

A human antibody that protects mice against a wide range of lethal flu viruses could be the key to a universal vaccine and better treatments for severe flu disease, according to a new study from Washington University School of Medicine in St. Louis, Icahn School of Medicine at Mount Sinai in New York City, and Scripps Research in La Jolla, Calif.


The research is published Oct. 25 in Science.

“There are many strains of influenza virus that circulate, so every year we have to design and produce a new vaccine to match the most common strains of that year,” said co-senior author Ali Ellebedy, PhD, an assistant professor of pathology and immunology at Washington University. “Now imagine if we could have one vaccine that protected against all influenza strains, including human, swine and highly lethal avian influenza viruses. This antibody could be the key to the design of a truly universal vaccine.”
Ellebedy discovered the antibody – an immune protein that recognizes and attaches to a foreign molecule – in blood taken from a patient hospitalized with flu at Barnes-Jewish Hospital in St. Louis in the winter of 2017. Ellebedy was working on a study analyzing the immune response to flu infection in humans, in collaboration with the Washington University Emergency Care and Research Core, which was sending him blood samples from consenting flu patients. He quickly noticed that this particular blood sample was unusual: In addition to containing antibodies against hemagglutinin, the major protein on the surface of the virus, it contained other antibodies that were clearly targeting something else.
“At the time we were just starting, and I was setting up my lab so we didn’t have the tools to look at what else the antibodies could be targeting,” said Ellebedy, who is also an assistant professor of medicine and of molecular microbiology.
He sent three of the antibodies with unknown targets to co-senior author Florian Krammer, PhD, a microbiology professor at the Icahn School of Medicine at Mount Sinai. An expert on neuraminidase – the other protein on the surface of the influenza virus – Krammer tested the antibodies against his extensive library of neuraminidase proteins. At least one of the three antibodies blocked neuraminidase activity in all known types of neuraminidase in flu viruses, representing a variety of human and nonhuman strains.
“The breadth of the antibodies really came as a surprise to us,” Krammer said. “Typically, anti-neuraminidase antibodies can be broad within a subtype, like H1N1, but an antibody with potent activity across subtypes was unheard of. At first, we did not believe our results. Especially the ability of the antibodies to cross between influenza A and influenza B viruses is just mind-boggling. It is amazing what the human immune system is capable of if presented with the right antigens.”
Neuraminidase is essential to flu virus replication. The protein cuts newly formed viruses free of infected cells so they can move on and infect new cells. Tamiflu, the most widely used drug for severe flu infection, works by inactivating neuraminidase.
To find out whether the antibodies could be used to treat severe cases of flu, Krammer and colleagues tested them in mice given a lethal dose of influenza virus. All three were effective against many strains, and one antibody – called 1G01 – protected mice against all 12 strains tested, representing all three groups of human flu virus, as well as avian and other nonhuman strains.
“All the mice survived, even if they were given the antibody 72 hours after infection,” Ellebedy said. “They definitely got sick and lost weight, but we still saved them. It was remarkable. It made us think that you might be able to use this antibody in an intensive care scenario when you have someone sick with flu and it’s too late to use Tamiflu.”
Tamiflu works best when administered within 48 hours of symptoms. A drug that could be used later would help many people diagnosed after the Tamiflu window has closed. But before the researchers could even think of designing such a drug based on the antibody, they needed to understand how it was interfering with neuraminidase.
They turned to co-senior author Ian Wilson, DPhil, a noted structural biologist at Scripps Research. Wilson and Xueyong Zhu, PhD, a staff scientist in his lab, mapped the structures of the antibodies while they were bound to neuraminidase. They found that the antibodies each had a loop that slid inside the active site of neuraminidase like a stick between gears. The loops prevented neuraminidase from releasing new virus particles from the surface of cells, thereby breaking the cycle of viral production in cells.
“We were surprised how these antibodies managed to insert a single loop into the conserved active site without contacting the surrounding hypervariable regions, thereby achieving much greater breadth against the neuraminidase of different influenza viruses than we have seen before,” Wilson said.
The structures showed that the antibodies provide such broad protection because they target parts of the active site of the neuraminidase protein that is much the same across distantly related flu strains. Even minor changes to that part of the protein could abolish its ability to do its job, thereby preventing the virus from replicating.
The researchers are working on developing new and improved treatments and vaccines for influenza based on antibody 1G01, which has been patented by Washington University.
“Neuraminidase has been ignored as a vaccine candidate for a long time,” Ellebedy said. “These antibodies tell us that it should not have been overlooked. Now that we know what a broadly protective antibody to neuraminidase looks like, we now have an alternative approach to start designing novel vaccines that induce antibodies like this. And that could be really important if we are going to figure out how to design a truly universal vaccine.”